Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya3371310.26442/00403660.2019.11.000307Editorial articleПередовая статьяReview ArticleTreatment of chronic viral hepatitis C with direct acting antiviral agent: reviewОсобенности лечения хронического вирусного гепатита C препаратами прямого противовирусного действия (обзор литературы)MalovV AМаловВалерий Анатольевич

д.м.н., проф., проф. каф. инфекционных болезней МПФ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0002-6157-1654

UbeevaE AУбееваЕлена Александровна

аспирант каф. фармакологии ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова»; ORCID: 0000-0002-9835-2279

UbeevaI PУбееваИраида Поликарповна

д.м.н., проф., проф. каф. инфекционных болезней ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова», ORCID: 0000-0001-8206-8436

NikolaevS MНиколаевСергей Матвеевич

д.м.н., проф., проф. каф. фармакологии ФБГОУ ВО «Бурятский государственный университет им. Доржи Банзарова», ORCID: 0000-0002-5833-7576

UmbetovaK TУмбетоваКарина Туракбаевна

д.м.н., проф. каф. инфекционных болезней МПФ ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0002-0902-9267

Sechenov First Moscow State Medical UniversityФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)Dorgi Banzarov Buryat State UniversityФБГОУ ВО «Бурятский государственный университет имени Доржи Банзарова» Министерства образования и науки151120199111VOL 91, NO11 (2019)ТОМ 91, №11 (2019)868916042020Copyright ©; 2019, Consilium MedicumCopyright ©; 2019, ООО "Консилиум Медикум"2019Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/33713

HCV infection treatment regimens are viewed from positions of HCV life cycle and replication, effects of NS3/4A protease inhibitors and NS5A/NS5B inhibitors on HCV strain replication. Evolution of HCV treatment regimens from its discovery to modern DAA agents had led to substantial progress although drug resistance poses a new issue to be addressed.

Изучение этапов жизненного цикла вируса гепатита С и процессов, составляющих его репликацию, привело к появлению новых классов препаратов прямого действия для противовирусной терапии: ингибиторов протеазы NS3/4A, полимеразы NS5A, NS5B. Рассматриваются типы препаратов прямого противовирусного действия, условия развития резистентности вируса и эволюция схем противовирусной терапии.

reviewantiviral therapyDAAviral resistanceобзоргепатит Спротивовирусная терапияпрепараты прямого противовирусного действиярезистентностьhepatitis СКлимова Е.А. Гепатит С. В кн.: Инфекционные болезни: национальное руководство. Под ред. Ющука Н.Д., Венгерова Ю.Я. М.: ГЭОТАР-Медиа, 2018:688-702.Пименов Н.Н., Комарова С.В., Карандашова И.В., Цапкова Н.А., Волчкова Е.В., Чуланов В.П. Гепатит C и его исходы в России: анализ заболеваемости, распространенности и смертности до начала программы элиминации инфекции. Инфекционные болезни. 2018;16(3):37-45. doi: 10.20953/1729-2018-3-37-45Kwo P.Y, Poordad F, Asatryan A, Wang S, Wyles D.L, Hassanein T, Felizarta F, Sulkowski M.S, Gane E, Maliakkal B, Overcash J.S, Gordon S.C, Muir A.J, Aguilar H, Agarwal K, Dore G.J, Lin C.W, Liu R, Lovell S.S, Ng T.I, Kort J, Mensa F.J. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263-71. doi: 10.1016/j.jh ep.2017.03.039Baatarkhuu O, Kim D.Y, Ahn S.H, Nymadawa P, Dahgwahdorj Y, Shagdarsuren M, Park J.Y, Choi J.W, Oyunbileg J, Oyunsuren T, Han K.H. Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population - based nationwide study. Liver Int. 2008;28(10):1389-95. doi: 10.1111/j.1478-3231.2008.01820.xQureshi H, Bile K.M, Jooma R, Alam S.E, Afridi H.U. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16(Suppl):S15-S23.Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57. doi: 10.1016/j.jhep.2014.07.027Spradling P.R, Rupp L, Moorman A.C, Lu M, Teshale E.H, Gordon S.C, Nakasato C, Boscarino J.A, Henkle E.M, Nerenz D.R, Denniston M.M, Holmberg S.D; Chronic Hepatitis Cohort Study Investigators. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55(8):1047-55. doi: 10.1093/cid/cis616Manns M.P, Buti M, Gane E, Pawlotsky J.M, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17006. doi: 10.1038/ nrdp.2017.6European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325-36. doi: 10.1016/S2468-1253(17)30045-6Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-41. doi: 10.3748/wjg.v13.i17.2436Рекомендации по диагностике и лечению взрослых больных гепатитом С. Ющук Н.Д. и др. М.:ГЭОТАР-Медиа, 2017.Stanaway J.D, Flaxman A.D, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad L.J, Assadi R, Bhala N, Cowie B, Forouzanfour M.H, Groeger J, Hanafiah K.M, Jacobsen K.H, James S.L, Mac Lachlan J, Malekzadeh R, Martin N.K, Mokdad A.A, Mokdad A.H, Murray C.J.L, Plass D, Rana S, Rein D.B, Richardus J.H, Sanabria J, Saylan M, Shahraz S, So S, Vlassov V.V, Weiderpass E, Wiersma S.T, Younis M, Yu C, E.l Sayed Zaki M, Cooke G.S. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-8. doi: 10.1016/ S0140-6736(16)30579-7Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon S.C, Schultz M, Davis M.N, Kayali Z, Reddy K.R, Jacobson I.M, Kowdley K.V, Nyberg L, Subramanian G.M, Hyland R.H, Arterburn S, Jiang D, McNally J, Brainard D, Symonds W.T, McHutchison J.G, Sheikh A.M, Younossi Z, Gane E.J. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87. doi: 10.1056/NEJMoa1214853Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9Reau N, Kwo P.Y, Rhee S, Brown R.S. Jr, Agarwal K, Angus P, Gane E, Kao J.H, Mantry P.S, Mutimer D, Reddy K.R, Tran T.T, Hu Y.B, Gulati A, Krishnan P, Dumas E.O, Porcalla A, Shulman N.S, Liu W, Samanta S, Trinh R, Forns X. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018;68(4):1298-307. doi: 10.1002/ hep.30046Scheel T.K, Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nature Medicine. 2013;19(7):837-49. doi: 10.1038/nm.3248Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285(5424):110-3.Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette J.C, Opolon P. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum. 1999;42(10): 2204-12.Thein H.H, Yi Q, Dore G.J, Krahn M.D. Estimation of stage - specific fibrosis progression rates in chronic hepatitis C virus infection: a meta - analysis and meta - regression. Hepatology. 2008;48(2):418-31. doi: 10.1002/hep.22375Takehara T, Hayashi N, Mita E, Hagiwara H, Ueda K, Katayama K, Kasahara A, Fusamoto H, Kamada T. Detection of the minus strand of hepatitis C virus RNA by reverse transcription and polymerase chain reaction: Implications for hepatitis C virus replication in infected tissue. Hepatology. 1992;15(3):387-90.Revie D, Salahuddin S.Z. Human cell types important for Hepatitis C Virus replication in vivo and in vitro: old assertions and current evidence. Virol J. 2011;8:346. doi: 10.1186/1743-422X-8-346Everson G.T, Towner W.J, Davis M.N, Wyles D.L, Nahass R.G, Thuluvath P.J, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, Mc Nally J, Brainard D.M, Han L, Doehle B, Mc Hutchison J.G, Morgan T, Chung R.T, Tran T.T. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015;163(11):818-26. doi: 10.7326/M15-1000Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects. https://clinicaltrials.gov/ct2/show/ NCT03092375Owens C.M, Brasher B.B, Polemeropoulos A, Rhodin M.H, Mc Allister N, Wong K.A, Jones C.T, Jiang L, Lin K, Or Y.S. Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor. Antimicrob Agents Chemother. 2016;60(10):6216-26. doi: 10.1128/AAC.00815-16Forns X, Lee S.S, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson D.R, Yu Y, Krishnan P, Lin C.W, Kort J.J, Mensa F.J. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single - arm, open - label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062-8. doi: 10.1016/ S1473-3099(17)30496-6Zeuzem S, Foster G.R, Wang S, Asatryan A, Gane E, Feld J.J, Asselah T, Bourlière M, Ruane P.J, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang W.L, Stedman C.A, Flamm S, Kwo P, Dore G.J, Sepulveda-Arzola G, Roberts S.K, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas H.E, Bruck R, Fuster F, Paik S.W, Felizarta F, Kort J, Fu B, Liu R, Ng T.I, Pilot-Matias T, Lin C.W, Trinh R, Mensa F.J. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378(4):354-69. doi: 10.1056/ NEJMoa1702417Kwo P.Y, Poordad F, Asatryan A, Wang S, Wyles D.L, Hassanein T, Felizarta F, Sulkowski M.S, Gane E, Maliakkal B, Overcash J.S, Gordon S.C, Muir A.J, Aguilar H, Agarwal K, Dore G.J, Lin C.W, Liu R, Lovell S.S, Ng T.I, Kort J, Mensa F.J. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67(2):263-71. doi: 10.1016/j.jhep.2017.03.039Wilson E, et al. Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience (RESOLVE). https://clinicaltrials.gov/ct2/show/NCT02745535Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri M.I, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M. Chronic hepatitis C: This and the new era of treatment. World J Hepatol. 2016;8(2):92-106. doi: 10.4254/wjh.v8.i2.92Foster G.R, Afdhal N, Roberts S.K, Bräu N, Gane E.J, Pianko S, Lawitz E, Thompson A, Shiffman M.L, Cooper C, Towner W.J, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman C.A, Mo H, Dvory-Sobol H, Han L, Wang J, Mc Nally J, Osinusi A, Brainard D.M, Mc Hutchison J.G, Mazzotta F, Tran T.T, Gordon S.C, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608-17. doi: 10.1056/NEJMoa1512612Manns M.P, Cornberg M. Sofosbuvir: the final nail in the coffin for hepatitis C? Lancet Infect Dis. 2013;13(5):378-9. doi: 10.1016/S1473-3099(13)70074-4Feld J.J, Jacobson I.M, Hézode C, Asselah T, Ruane P.J, Gruener N, Abergel A, Mangia A, Lai C.L, Chan H.L, Mazzotta F, Moreno C, Yoshida E, Shafran S.D, Towner W.J, Tran T.T, Mc Nally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard D.M, Mc Hutchison J.G, Agarwal K, Zeuzem S; ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599-607. doi: 10.1056/NEJMoa 1512610El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol. 2016; 9(11):1413-21. doi: 10.1080/17512433.2016.1233813Asselah T, Kowdley K.V, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry P.S, Hezode C, Marinho R.T, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng T.I, Krishnan P, Lin C.W, Mensa F.J. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-26. doi: 10.101 6/j.cgh.2017.09.027Kliemann D.A, Tovo C.V, da Veiga A.B, de Mattos A.A, Wood C. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol. 2016;22(40):8910-7. doi: 10.3748/wjg.v22.i40.8910Апросина З.Г. Хронический активный гепатит как системное заболевание. М.: Медицина, 1981.Chung R.T, et al. Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant. https://clinicaltrials.gov/ct2/show/ NCT03623568Cacoub P, Commarmond C, Sadoun D, Desbois A.C. Hepatitis C virus infection and rheumatic diseases: the impact of direct - acting antiviral agents. Rheum Dis Clin North Am. 2017;43(1):123-32. doi: 10.1016/j.rdc.2016.09.011Negro F, Forton D, Craxi A, Sulkowski M.S, Feld J.J, Manns M.P. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-60. doi: 10.1053/j.gastro.2015.08.035